Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Crizocent 250
Incepta Pharmaceuticals Ltd.
Generic: Crizotinib
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Crizocent 250. Please consult your doctor.
CONSULT YOUR DOCTOR
Crizocent 250 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Crizocent 250 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
UNSAFE
Crizocent 250 may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
CAUTION
Crizocent 250 should be used with caution in patients with severe kidney disease. Dose adjustment of Crizocent 250 may be needed. Please consult your doctor.
CAUTION
Crizocent 250 should be used with caution in patients with liver disease. Dose adjustment of Crizocent 250 may be needed. Please consult your doctor.
Use of Crizocent 250 may not be advised in patients with the severe liver disease.
Medicine Overview of Crizocent 250mg Capsule
Introduction
Crizocent 250 is used in the treatment of non-small cell lung cancer that is locally advanced or has spread to other areas of the body. Crizocent 250 should be taken with food or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way...
... Show moreUses of Crizocent 250
- Non-small cell lung cancer
Side effects of Crizocent 250
Common
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Visual impairment
- Dizziness
- Taste change
- Fatigue
- Decreased appetite
- Rash
- Decreased white blood cell count (neutrophils)
How to use Crizocent 250
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Crizocent 250 may be taken with or without food, but it is better to take it at a fixed time.
How Crizocent 250 works
Crizocent 250 is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
What if you forget to take Crizocent 250?
If you miss a dose of Crizocent 250, skip it and continue with your normal schedule. Do not double the dose.
Quick Tips
- Crizocent 250 helps in the treatment of non-small cell lung cancer that is locally advanced, or has spread to other areas of the body.
- Take it at the same time each day, with or without food.
- Diarrhea, nausea and vomiting may occur with Crizocent 250. Stay hydrated and inform your doctor if it persists.
- It may cause dizziness or blurring of vision. Don't drive or do anything requiring concentration until you know how it affects you.
- Inform your doctor if you experience severe stomach pain, fever, chills, shortness of breath, fast heartbeat, partial or complete loss of vision or changes in bowel habits.
- Your doctor may want you to have regular blood tests to monitor your liver function while you are having treatment with this medicine.
- Do not take Crizocent 250 if you are pregnant or breastfeeding. Use reliable methods of contraception to prevent pregnancy while taking this medicine.
Brief Description
Indication
Non-Small Cell Lung Cancer, Indicated for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive
Indicated for metastatic NSCLC tumors that are ROS1-positive
Administration
Take with or without food; a high-fat meal reduces AUCinf and Cmax by ~14%
Capsules should be swallowed whole
Adult Dose
Oral Adult Non-Small Cell Lung Cancer Indicated for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Also indicated for metastatic NSCLC tumors that are ROS1-positive. Select patients for treatment of metastatic NSCLC based on presence of ALK or ROS1 positivity in tumor specimens. Capsule 250 mg PO q12hr Continue treatment as long as patient is deriving clinical benefit from therapy Dose Modifications Dosing interruption and/or dose reduction to 200 mg PO q12hr may be required based on safety and tolerability; decrease to 250 mg PO...
... Show moreChild Dose
Safety and efficacy not established
Renal Dose
Renal impairment
Mild-to-moderate (CrCl 30-90 mL/min): No starting dose adjustment is needed; steady-state trough concentrations in these 2 groups were similar to those with normal renal function (ie, CrCl >90 mL/min)
Severe (CrCl <30 mL/min) or end-stage renal disease: Caution advised
Contraindication
Hypersensitivity
Mode of Action
Inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON)
The gene’s expression and signaling that contribute to increased cell proliferation and survival of the tumors become activated following the expression of ALK oncogenic fusion proteins
Inhibits the signaling that promotes the expression of these oncogenic fusion proteins, thereby inhibiting tumor cell proliferation
Precaution
Severe, including fatal, treatment-related pneumonitis reported; monitor for pulmonary symptoms indicative of pneumonitis and permanently discontinue if diagnosed Hepatoxicity reported; elevations in ALT and total bilirubin reported; monitor q2wk for 2 months, then monthly and as clinically indicated with more frequent testing with Grade 2-4 elevations; temporarily suspend, reduce dose, or permanently discontinue dose as indicated (see Dose Modifications) Symptomatic bradycardia reported, including syncope; avoid coadministration with other drugs known to cause bradycardia; monitor heart rate and blood pressure regularly; temporarily suspend, reduce dose, or permanently discontinue (see Dosage Modifications) Caution when driving or operating machinery because of vision disorder,...
... Show moreSide Effect
>10%
ALT elevation (76%),AST elevation (61%),Vision disorder (60%),Diarrhea (60%),Nausea (55%),Lymphopenia (51%),Neutropenia (49%),Vomiting (47%),Constipation (42%),Edema (31%),Hypophosphatemia (28%),Decreased appetite (27%),Fatigue (27%),Dysgeusia (26%),Upper respiratory infection (26%),Dizziness (22%),Neuropathy (19%),Dysesthesia (19%),Gait disturbance (19%),Hypoesthesia (19%),Muscular weakness (19%),Neuralgia (19%),Peripheral neuropathy (19%),Paresthesia (19%),Peripheral sensory neuropathy (19%),Polyneuropathy (19%),Burning sensation in skin (19%),Hypokalemia (18%)
1-10%
Weight decreased (10%),Rash (9%),Dyspepsia (8%),Pulmonary embolism (6%),QT prolongation (5%),Bradycardia (5%),Pneumonia (4.1%),Pneumonitits (4%),Renal cyst (4%),ARDS (4%),Pulmonary embolism (3.5%),Syncope (3%),Dyspnea (2.3%),Hepatic failure (1%),Esophagitis (2%)
<1%
Vision loss, grade 4 (0.2%),Hypogonadism; decreased blood testosterone (1%)
Pregnancy Category Note
Pregnancy
Based on its mechanism of action, can cause fetal harm when administered to a pregnant woman
Contraception
Advise females of reproductive potential to use effective contraception during treatment and for at least 45 days following the final dose
Advise males taking crizotinib with female partners of reproductive potential to use condoms during treatment and for at least 90 days after the final dose
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
